Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 681-691

  Henley III, Charles ^a   Yang, Yuhua ^a   Davis, James ^a   Lu, Jenny Ying Lin ^a   Morony, Sean ^a   Fan, Wei ^a   Florio, Monica ^a   Sun, Banghua ^a   Shatzen, Edward ^a   Pretorius, James K ^a   Richards, William G ^a   St Jean Jr , David J ^a   Fotsch, Christopher ^a   Reagan, Jeff D ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIMIMETIC B; CALCITONIN; CALCIUM ION; MITOGEN ACTIVATED PROTEIN KINASE; PARATHYROID HORMONE; TECALCET; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CANCER CELL CULTURE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; ENZYME PHOSPHORYLATION; FEMALE; HORMONE INHIBITION; HUMAN; HUMAN CELL; HYPOCALCEMIA; MALE; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; THYROID CARCINOMA;

ANILINE COMPOUNDS; ANIMALS; BIPHENYL COMPOUNDS; CALCITONIN; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; DIETHYLAMINES; HEK293 CELLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; INOSITOL PHOSPHATES; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS;

EID: 79956218684     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.178681     Document Type: Article

References (37)

1. Alon US and VandeVoorde RG (2010) Beneficial effect of cinacalcet in a child with familial hypocalciuric hypocalcemia. Pediatr Nephrol 25:1747-1750.
2. Antonsen JE, Sherrard DJ, and Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 53:223-227. (Pubitemid 28066926)
3. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
4. Baylink D, Morey E, and Rich C (1969) Effect of calcitonin on the rates of bone formation and resorption in the rat. Endocrinology 84:261-269.
5. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525. (Pubitemid 38477776)
6. 2+ and other ions as extracellular (first) messengers. Physiol Rev 71:371-411.
7. Brown EM (2007) Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3:122-133.
8. 2+ sensing receptor from bovine parathyroid. Nature 366:575-580.
9. 2+-sensing receptors-an overview. Cell Calcium 35:183-196.
10. Chen CJ, Barnett JV, Congo DA, and Brown EM (1989) Divalent cations suppress 3′, 5′-adenosine monophosphate accumulation by stimulating a pertussis toxinsensitive guanine nucleotide-binding protein in cultured bovine parathyroid cells. Endocrinology 124:233-239. (Pubitemid 19033651)
11. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, et al. (2009) A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53:197-207.
12. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharm Sci 19:351-357.
13. Dufner MM, Kirchhoff P, Remy C, Hafner P, Müller MK, Cheng SX, Tang LQ, Hebert SC, Geibel JP, and Wagner CA (2004) The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands. Am J Physiol Gastrointest Liver Physiol 289:G1084-G1090.
14. Festen-Spanjer B, Haring CM, Koster JB, and Mudde AH (2008) Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Clin Endocrinol (Oxf) 68:324-325.
15. Fox J, Lowe SH, Conklin RL, Petty BA, and Nemeth EF (1999a) Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptor in rats. J Pharmacol Exp Ther 290:480-486. (Pubitemid 29344537)
16. Fox J, Lowe SH, Petty BA, and Nemeth EF (1999b) NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290: 473-479. (Pubitemid 29344536)
17. Garrett JE, Tamir H, Kifor O, Simin RT, Rogers KV, Mithal A, Gagel RF, and Brown EM (1995) Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 136:5202-5211.
18. Geibel J, Sritharan K, Geibel R, Geibel P, Persing JS, Seeger A, Roepke TK, Deichstetter M, Prinz C, Cheng SX, et al. (2006) Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proc Natl Acad Sci 103:9390-9397. (Pubitemid 43955837)
19. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, and Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024. (Pubitemid 34274098)
20. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53:1083-1088.
21. Harrington PE, St Jean DJ Jr, Clarine J, Coulter TS, Croghan M, Davenport A, Davis J, Ghiron C, Hutchinson J, Kelly MG, et al. (2010) The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core. Bioorg Med Chem Lett 20:5544-5557.
22. 2+ concentrations on the levels of inositol 1,3,4,5-tetrakisphosphate in bovine parathyroid cells. Endocrinology 124:838-844.
23. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, and Martin D (2005) 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20:1370-1377. (Pubitemid 41430610)
24. 2+-sensing receptor (CaR) activates phospholipases C, A2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J Bone Miner Res 12:715-725.
25. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389. (Pubitemid 47087967)
26. Leong SS, Horoszewicz JS, Shimaoka K, Friedman M, Kawinski E, Song MJ, Zeigel R, Chu TM, Baylin S, and Mirand EA (1981) A new cell line for study of human medullary thyroid carcinoma, in Advances in Thyroid Neoplasia (Andreoli M, Monaco F, and Robbins J, eds) pp 95-108, Field Education, Rome.
27. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, and Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31-38. (Pubitemid 44967731)
28. Lu JY, Yang Y, Gnacadja G, Christopoulos A, and Reagan JD (2009) Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)- 1- propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J Pharmacol Exp Ther 331:775-786.
29. Makita N, Sato J, Manaka K, Shoji Y, Oishi A, Hashimoto M, Fujita T, and Iiri T (2007) An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. Proc Natl Acad Sci USA 104:5443-5448. (Pubitemid 47175699)
30. Nemeth EF and Fox J (1999) Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10:66-71. (Pubitemid 29287825)
31. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, et al. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627-635. (Pubitemid 38134225)
32. Nishiki K, Tsuruoka S, Wakaumi M, Yamamoto H, Koyama A, and Fujimura A (2003) Dosing time-dependent variation in the hypocalcemic effect of calcitonin in rat. Eur J Pharmacol 460:171-175. (Pubitemid 36139985)
33. 2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 279:18990-18997.
34. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP, et al. (2007) Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 282:18028-18036. (Pubitemid 47100250)
35. Sorensen OH, Hellesen C, and Hindberg I (1970) The effect of diet and age on the response to calcitonin in rats. Acta Endocrinol 65:316-322.
36. Timmers HJ, Karperien M, Hamdy NA, de Boer H, and Hermus AR (2006) Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 260:177-182. (Pubitemid 44051343)
37. Wilcox JN (1993) Fundamental principles of in situ hybridization. J Histochem Cytochem 41:1725-1733.